来那度胺和泊马度胺增强AMG 701在多发性骨髓瘤临床前模型中的效力
本研究探讨双特异性T细胞衔接分子AMG 701联合免疫调节药物(来那度胺、泊马度胺)的抗多发性骨髓瘤(MM)作用。AMG 701可诱导针对表达B细胞成熟抗原的MM细胞(包括复发难治患者自体细胞)的T细胞依赖性细胞毒性,半数有效浓度<46.6 pM。IMiDs与AMG 701协同增强细胞毒性,并促进T细胞记忆表型分化,联合来那度胺在人T细胞重建SCID小鼠中持续抑制肿瘤生长(P < .001)。
要点
- AMG 701单药对复发难治MM患者自体细胞具有强效T细胞依赖性细胞毒性。
- 来那度胺或泊马度胺与AMG 701协同增强抗MM活性,并促进T细胞记忆分化。
- 联合来那度胺在体内持续抑制肿瘤生长,支持AMG 701单药及联合IMiDs的临床研究。
核心结论
- AMG 701联合来那度胺或泊马度胺可协同增强抗多发性骨髓瘤活性,并促进T细胞记忆表型分化。
- 联合来那度胺在体内持续抑制肿瘤生长,支持AMG 701单药及联合IMiDs的临床研究。
研究设计与样本
- 临床前研究,体外评估AMG 701单药及联合IMiDs对MM细胞系和复发难治MM患者自体细胞的效应。
- 体内使用人T细胞重建的SCID小鼠模型评估联合来那度胺的抑瘤效果。
主要发现
- AMG 701诱导针对表达B细胞成熟抗原的MM细胞(包括复发难治患者自体细胞)的T细胞依赖性细胞毒性,半数有效浓度<46.6 pM。
- AMG 701促进患者T细胞向中央记忆、效应记忆和干细胞样记忆表型分化,CD8亚群较CD4亚群更明显,7天体外共培养中CD8/CD4比值增加。
- IMiDs与AMG 701协同诱导针对MM细胞系和复发难治患者自体细胞的T细胞依赖性细胞毒性,即使在免疫抑制性骨髓基质细胞或破骨细胞存在下仍有效。
- IMiDs进一步上调AMG 701诱导的患者T细胞向记忆表型分化,伴随CD8/CD4比值增加、干细胞样记忆T细胞增加、白细胞介素10阳性T细胞和调节性T细胞(CD25highFOXP3high)减少。
- AMG 701联合来那度胺在人T细胞重建SCID小鼠中持续抑制MM细胞生长,单药治疗组最终观察到肿瘤再生长(P < .001)。
临床怎么用
- 支持AMG 701作为单药在复发难治MM患者中开展临床研究(NCT03287908)。
- 支持AMG 701联合IMiDs以改善MM患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated here the novel immunomodulation and anti-multiple myeloma (MM) function of T cells engaged by the bispecific T-cell engager molecule AMG 701, and further examined the impact of AMG 701 in combination with immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide). AMG 701 potently induced T-cell-dependent cellular cytotoxicity (TDCC) against MM cells expressing B-cell maturation antigen, including autologous cells from patients with relapsed and refractory MM (RRMM) (half maximal effective concentration, <46.6 pM). Besides inducing T-cell proliferation and cytolytic activity, AMG 701 also promoted differentiation of patient T cells to central memory, effector memory, and stem cell-like memory (scm) phenotypes, more so in CD8 vs CD4 T subsets, resulting in increased CD8/CD4 ratios in 7-day ex vivo cocultures. IMiDs and AMG 701 synergistically induced TDCC against MM cell lines and autologous RRMM patient cells, even in the presence of immunosuppressive bone marrow stromal cells or osteoclasts. IMiDs further upregulated AMG 701-induced patient T-cell differentiation toward memory phenotypes, associated with increased CD8/CD4 ratios, increased Tscm, and decreased interleukin 10-positive T and T regulatory cells (CD25highFOXP3high), which may downregulate T effector cells. Importantly, the combination of AMG 701 with lenalidomide induced sustained inhibition of MM cell growth in SCID mice reconstituted with human T cells; tumor regrowth was eventually observed in cohorts treated with either agent alone (P < .001). These results strongly support AMG 701 clinical studies as monotherapy in patients with RRMM (NCT03287908) and the combination with IMiDs to improve patient outcomes in MM.
引用
- Cho SF, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020. PMID: 32898244. doi:10.1182/bloodadvances.2020002524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。